Defects of the SCN5A gene encoding the cardiac sodium channel alpha subunit are associated with both the LQT-3 subtype of long-QT syndrome and Brugada syndrome (BrS). One previously described SCN5A mutation (1795insD) in the C-terminus results in a clinical phenotype combining QT prolongation and ST segment elevation indicating a close interrelationship between the two disorders (1). Here we provide additional evidence that these two disorders are closely related. We report the analysis of two novel mutations on the same codon, Y1795C (LQT-3) and Y1795H (BrS), expressed in HEK 293 cells and characterized using whole-cell patch clamp procedures. We find marked and opposing effects on channel gating consistent with activity associated with the cellular basis of each clinical disorder. Y1795H speeds and Y1795C slows the onset of inactivation. The Y1795H, but not the Y1795C, mutation causes a marked negative shift in the voltage-dependence of inactivation, and neither mutation affects the kinetics of the recovery from inactivation. Interestingly, both mutations increase the expression of sustained Na + channel activity compared with wild type (WT) channels, although this effect is most pronounced for the Y1795C mutation, and both mutations promote entrance into an intermediate or slowly-developing, inactivated state. These data confirm the key role of the C-terminal tail of the cardiac Na + channel in the control of channel gating; illustrate how subtle changes in channel biophysics can have significant and distinct effects in human disease; and, additionally, provide further evidence of the close interrelationship between BrS and LQT-3 at the molecular level.
Introduction
Mutations of SCN5A, the gene coding for the alpha subunit of the cardiac sodium channel, have been linked to four human syndromes: congenital long QT syndrome type 3 (LQT-3), Brugada syndrome (BrS), different types of conduction block (2) and sudden infant death syndrome (SIDS) (3) (4) (5) (6) (7) . Despite this classification based on clinical characteristics such as ECG findings, age of first presentation, triggers of events and others, significant clinical and pathophysiological overlap between these different disorders have been noted recently. This observation has led to the proposition that these syndromes are in fact only different appearances of a "unique" SCN5A disease.
The most significant overlap exists between LQT-3 and the BrS (8) . The most frequent presentation in both disorders is a history of syncope or cardiac arrests with a very high lethality, occurring mainly during rest or sleep and with a poor response to antiadrenergic treatment such as beta receptor blockade (9) (10) (11) (12) . However, the typical electrocardiographic manifestations of long-QT syndrome (QT interval prolongation) and BrS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BrS (8) .
Moreover, in some LQT-3 patients, exposure to the sodium channel blocker flecainide generates an ECG pattern that is very similar to the BrS (8) .
By definition LQT-3 is caused by mutations found in SCN5A, while, to date, all mutations linked with BrS are also in this gene. Multiple SCN5A mutations linked to both disorders have now been reported and characterized (13;14) . The most common alteration in channel function caused by LQT-3 mutations is the induction of sustained Na channel activity over the time course and voltage-range of the ventricular action potential plateau phase first described by Bennett et al. for the ∆KPQ LQT-3 mutation (15;16) . It is generally thought that mutation-induced loss of channel activity underlies the cellular and clinical phenotype of BrS(5) (17) (18) (19) (20) . Nevertheless, these functional changes, although sufficient, may not always be necessary to cause clinically either LQT-3 or BrS (21) , and it is possible that other, as yet undiscovered, genetic factors are likely to contribute to the expression of the specific disease phenotypes in these patients. Here we report and characterize two novel point mutations of SCN5A in the same codon (Y1795) that were identified in patients clinically classified as LQT-3 (Y1795C) and BrS (Y1795H) cases.
Functional analysis of these cardiac sodium channel mutations expressed in HEK 293 cells indicates marked and opposing effects on the kinetics and voltage-dependence of the inactivated state of the expressed channels consistent with the disease phenotypes.
Interestingly, both mutations also confer some biophysical properties upon the expressed channels that are not generally associated with the observed clinical phenotypes.
Methods

Molecular screening
Genomic DNA was extracted from peripheral blood lymphocytes by standard techniques. The coding region of the SCN5A gene encoding the cardiac Na + channel a subunit was screened using single strand conformation polymorphism (SSCP) on PCR amplified genomic DNA samples. The abnormal conformers were directly sequenced on both strands using an ABI310 genetic analyzer or cloned (TopoTA cloning, Invitrogen) and sequenced using plasmid-specific oligonucleotides. SSCP shifts were also checked against a panel of genomic DNA from 300 (600 chromosomes) healthy reference individuals and were not found in this group.
Mutagenesis and expression of recombinant Na + channels
The Y1795C and Y1795H mutations of SCN5A were engineered into WT cDNA cloned in pcDNA3.1 (Invitrogen) by overlap extension using mutation-specific primers and Quick Change Site-Directed Mutagenesis Kit (Stratagene). The presence of the mutation was confirmed by sequence analysis. WT and mutant Na + channels were expressed in HEK293 cells as previously described. Transient transfections were carried out with equal amounts of Na + channel α subunit and with hβ 1 , subcloned individually into the pcDNA3.1 (Invitrogen) vector (total cDNA 2.5 mg) using a previously described lipofection procedure.
Expression of channels was studied using patch clamp procedures 48 hours after transfection.
Electrophysiology
Membrane currents were measured using whole cell patch-clamp procedures, with Axopatch 200B amplifiers (Axon Instruments, Foster City, CA). Recordings were made at room temperature (22 °C) or 32°C where indicated. Internal pipette solution contained (in mmol/L): aspartic acid 50,CsCl 60, Na 2 -ATP 5, EGTA 11, HEPES 10, CaCl 2 1, and MgCl 2 1, with pH 7.4 adjusted with CsOH (22) . External solutions (full Na + ) consisted of (mmol/L) NaCl 130, CaCl 2 2, CsCl 5, MgCl 2 1.2, HEPES 10, and glucose 5, with pH 7.4 adjusted with CsOH. In experiments designed to measure the voltage dependence of activation, external Na + was reduced to 30 mM using n-methylglucamine as a Na + substitute. Holding potentials were -100 mV or -120 mV as indicated in figure captions. Pclamp8 (Axon Instruments, Foster City, CA); Excel (Microsoft, Seattle, WA); and Origin6 (Microcal Software, Northampton, MA) were used for data acquisition and analysis. Data for the voltage dependence of activation were fitted with Boltzmann relationships and data for the time course of recovery from inactivation were fitted with functions of two exponentials using Origin as previously described by us (23) . Data are presented as mean values ± SEM. Two-tailed Student's t test was used to compare means; P<0.05 was considered statistically significant (23;23) .
Results
Description of new LQT-3 and BrS mutations
We report two novel mutations identified at codon Y1795 of the SCN5A gene. The mutation Y1795C (substitution of a tyrosine by a cysteine, Y1795C) was found to be linked with an LQTS clinical phenotype, and the mutation Y1795H (tyrosine replace by an histidine residue, Y1795H) was linked to a BrS phenotype (see below). Interestingly, these two mutations are found in the same codon of the (Y1795) C-terminus tail of the cardiac sodium channel (Fig. 1) where an insertion mutation (1795insD) has been shown to be linked to both BrS and LQT-3, depending on physiological conditions of the mutation carrier such as heart rate (1). Additionally other LQT-3 (i.e. E1748K, D1790G)(24) (1; 25;26) BrS (A1924T) (27) mutations have been reported in the C-terminal tail of the channel indicating its importance in the control of channel gating.
Characterization of the Y1795C family (LQT-3)
The proband is a 42 year old female asymptomatic for arrhythmias but presenting a long QT interval on the ECG (Figure 2A 
Characterization of the Y1795H family (BrS)
The proband is a 45 years old white male asymptomatic for palpitations, syncope or cardiac arrest with a negative family history for juvenile (<40 years) cardiac arrest, syncope or known ventricular arrhythmias. The ECG recording ( Figure 2B 
Functional properties of Y1795C and Y1795H mutant channels
We expressed Y1795H and Y1795C mutant channels in HEK 293 cells and investigated their functional properties using the whole-cell configuration of the patch clamp procedure. Figure 3 Normalized current/voltage (I/V) relationships for WT, Y1795H, and Y1795C channels shown in Figure 3C superimpose suggesting that neither mutation affects the voltagedependence of activation. We also tested the effects of the mutations on current densities and found that the mutations had opposite effects on the magnitude of expressed current. YC mutant channels were expressed at a slightly higher density (-448±43 pA/pF, n=17) than WT channel (-370±32 pA/pF, n=29), but YH channels were expressed at significantly (p<0.05) lower density (-244±15 pA/pF, n=30). These mutation-induced changes in current density are consistent with expected properties underlying each clinical disorder. Figure 4A confirms little effect on the voltagedependence of activation caused by either the Y1795H or Y1795C mutation, but in contrast, shows that the Y1795H, but not the Y1795C, mutation causes a hyperpolarizing shift in the voltage-dependence of inactivation. Inactivation curves shown in the figure were obtained from a -100 mV holding potential using 500 ms conditioning pulses. We obtained similar effects of the mutations on inactivation curves measured from -120 mV holding potentials and after 50 ms or 10 ms conditioning pulses (not shown) indicating that the effects of the YH mutation are primarily due to changes in the voltage-dependence of fast inactivation. We tested for, but did not find, mutation-induced changes in the recovery from inactivation using a paired pulse protocol ( Figure 4B ).
We next tested for mutation-induced sustained Na + activity, and summarize these results in Figure 5 . In these experiments, we focused on currents measured at -10 mV which is near the peak voltage of the I/V relationship to optimize resolution of small currents and measured tetrodotoxin (TTX)-sensitive current to ensure subtraction of time-independent leakage currents. Similar to other LQT-3 mutant channels such as the ∆KPQ channel(31), sustained TTX-sensitive current was detected for Y1795C (LQT-3) channels at a magnitude approximately 4-5 times greater than for WT channels. This large effect on maintained current is consistent with a cellular phenotype of action potential prolongation necessary to cause LQTS (16) . However, surprisingly, we also find that the Y1795H (BrS) mutation causes a small, but significant increase in sustained Na + activity relative to WT channels, although this effect is only about half of that caused by the Y1795C mutation.
Both the 1795insD and T1620M BrS mutations of SCN5A have been shown to enhance the entry of expressed channels into an "intermediate" inactivated state, "Im", that develops slowly during membrane depolarization over time periods consistent with the plateau phase of the ventricular action potential (∼ 500 ms) (32;33) . Under conditions of rapid heart rate (tachycardia), an intermediate inactivated state might contribute to a decrease in Na + channel current, consistent with a cellular phenotype associated with the Brugada syndrome(17). We thus tested for an effect of the Y1795H mutation on the slow development of inactivation using previously described protocols (33) and summarize the results in Figure 6 . We used a protocol to detect changes in the onset of Im inactivation by applying conditioning pulses of a common amplitude but variable duration before assaying available current with a test pulse. A 20 ms return to the holding potential is used to remove most fast inactivation that develops during the prepulses. As was the case for previous studies, we found little Im inactivation developing for either WT or mutant channels at room temperature for conditioning pulses up to 3 sec in duration (data not shown). However, at more physiological temperatures, we were able to detect significantly greater slowly developing Im inactivation for Y1795H vs WT channels ( Figure 6A ) similar to the previously-investigated BrS mutant channels (32) . At sufficiently prolonged conditioning times, there was a greater tendency for YH channels to inactivate that YC channels.
The observation of mutation-induced changes in intermediate inactivation raise the possibility that clinically-relevant functional properties of the mutant channels may be influenced by stimulation rate in voltage-clamp experiments, and heart rate in patients carrying the specific mutations. Consequently, we tested for the effect of pulse frequency on the amplitude (late current) and kinetics of mutant and wild type channels and summarize these data in Figure 6B and 7. Traces in the upper row are normalized to emphasize changes in kinetics; those in lower row are absolute currents to emphasize possible change in peak current. As expected due to slow inactivation, at this pulse rate there is reduction in peak current during the pulse train; but perhaps more interesting, the kinetic of YC, but not WT or YH, channels changes during the pulse train. Figure 7 presents the effect of repetitive activity at two frequencies on expressed channels.
These experiments were carried out by holding cells at -100 mV for 30 seconds under pulse free conditions after which test pulses were applied at the indicated frequencies.
Panel A shows superimposition of normalized currents measured in response to the first and last pulse of each train and at each pulse frequency. Only the waveform of YC currents are markedly affected by pulse frequency: at the 1.9 Hz, there is a reduction in the time course of inactivation that develops with repetitive pulsing. This is more apparent in Panel B which plots the time to 80% decay of initial current amplitude (T 80 ), vs. pulse number during this protocol. As indicated in the traces (A), but seen clearly in the plot, there is no change in the time course of YC channels at the slower pulse rate (0.67 Hz), but a pulse-dependent speeding at 1.9 Hz. Indicated in the figure for comparison are T 80 values for WT channels recorded under the same conditions (open squares, circles). In the steady state at the 1.9 Hz pulse frequency, the onset kinetics of YC channel approach those of WT channels; but both following a pause in stimulation (pulse 1) or in the steady state at the slower frequency (0.67 Hz) YC channels decay almost twice as slowly as WT channels. A similar trend is seen in the analysis of maintained current which is illustrated in Figure 7C . Maintained current through YC Robert S. Kass Page 14 06-11-01 channels is most prominent at the slower pulse frequency; is most problematic following a pause in stimulation, and approaches the magnitude of WT maintained current at higher stimulation frequencies. These experiments clearly show that, particularly for the case of the YC mutation, the stimulation rate of cellular experiments and heart rates of mutation carriers will be critical to expression of cellular and systems phenotypes.
Discussion
In this study we have presented further evidence of the close interrelationship in the molecular determinants of LQT-3 and BrS. We describe the functional consequences of two novel mutations of the same residue of the C-terminal portion of SCN5A linked to BrS (Y1795H) and LQT-3 (Y1795C). The most pronounced effects of the mutations are changes in channel gating that are consistent with the models that link channel to cellular to systems phenotypes for both and BrS (20) . Hence Y1795C mutant channels inactivate more slowly than WT channels and are characterized by a prominent fraction of current that is maintained during prolonged depolarization. Both of these changes in channel properties are expected to contribute more inward current during both the early and late phases of the action potential and hence are consistent with prolongation of the cellular action potential (16;34;35) . Similarly, the most pronounced effects of the Y1795H mutation are a negative shift in channel availability, a speeding of the onset of inactivation, particularly at voltages near threshold for channel activation, and a reduction in peak current density. These effects are consistent with a reduction in inward current in cells expressing mutant channels as required in models proposed by Antzelevitch et al, to explain ST segment elevation in BrS (20) .
We also found a small, but consistent and statistically significant, increase in maintained Na + channel activity caused by the Y1795H mutation. By itself, this effect on channel gating would be expected prolong the cellular action potential and accompanying QT interval in carriers of this gene defect. Despite this the dominant clinical phenotype leading to the discovery of this mutation was ST-segment elevation, and not QT prolongation.
Furthermore, when we investigated the effects of both mutations on the development of slow or intermediate inactivation, we found that both mutations promote this state of the channel to a degree that is significantly greater than WT channels. Because promotion of inactivation of the channel leads to eventual loss of channel activity, such a biophysical change would not be anticipated for an LQT-3 mutation, which would generally be considered linked to gain of function activity. However our data indicate that these effects would only be anticipated under conditions of rapid stimulation (high heart rates), and the LQT-3 proband did not present clinical characteristics linked to BrS such as ST elevation and or other evidence of right bundle branch block even during challenges with flecainide indicating that this reduction in current is not likely to be important under physiologically relevant conditions. On the other hand, our data for the YC mutation shows that biophysical properties that contribute to action potential duration (APD) prolongation, slowing of the onset of inactivation and the promotion of maintained Na + channel current are more pronounced at slower heart rates ( Figure 7 ) indicate that carriers of this mutation will be at greatest risk for prolonged APD-induced arrhythmias at slow heart rates. Thus the YC mutation, like other previously described LQT-3 mutations, is most problematic during bradycardia or following pauses in excitation of the ventricle (16;36-38) .
The biophysical duality of the Y1795H and Y1795C mutations in some ways resembles the duality demonstrated for the 1795insD mutation described by Veldkamp, et al. (33) . In the case of 1795insD, mutation-induced changes in an intermediate inactivated state of the channel reduce currents in a steeply heart-rate-dependent manner. Thus at low heart rates a maintained current is revealed and potentiated relative to WT channels, and at faster heart rates, overall channel activity is reduced relative to WT (33) . We detected an increase in maintained Na + channel activity for Y1795H mutant compared with WT channels which, even though much smaller in amplitude than similar activity induced by the Y1795C mutation, would contribute to delay in action potential repolarization. However, the overall reduction in the expression of YH channel activity ( Figure 5 ) apparently dominates the physiological impact of the mutation. The most pronounced biophysical consequence of the Y1795C mutation is the slowing of the onset of inactivation, which is accompanied by a marked increase in maintained channel activity. These two properties together are consistent with QT prolongation that characterizes the ECG of the proband, which as described above, is also markedly dependent on heart rate. At sufficiently fast rates, the YC mutant channels will conduct less maintained current (Figure 7 ), inactivate faster (Figure 7) , and, via enhanced Im inactivation (Figure 6 ), express less peak current than WT channels. Taken together, these effects, although predicted for very fast stimulation rates, would predict BrS and not LQT-3 functional consequences.
Together with the data of Veldkamp, et al. (33) , the present results (1) demonstrate the critical importance of residue Y1795 in controlling inactivation of the cardiac Na + channel and (2) provide further evidence of the close interrelationship between Na + channel properties that underlie BrS and LQT-3 in carriers of Na + channel mutations.
These mutations present an opportunity to dissect physiological conditions and pharmacological properties of the mutant channels that underlie expression of the distinct disease phenotypes both in the absence and presence of drug challenges.
Further evidence for the cross-over in mutation-induced channel properties and causal linkage to BrS and LQT-3
comes from a comparison of the properties of D1790G, another previously-described LQT-3 mutation of the Cterminus of the Na + channel α subunit, with those of the Y1795H BrS mutant channel. Both mutations speed the onset of inactivation and both mutations cause a negative shift in the voltage-dependence of steady-state channel availability. Furthermore, under the same recording conditions, the Y1795H, but not the D1790G, mutation increases sustained channel activity, but clinically the two mutations have been linked distinctly to BrS (Y1795H) and LQT-3 (D1790G). A recent analysis of the D1790G channel using distinctly different intracellular recording conditions and a different cell line has revealed that, under these conditions, this mutation can promote sustained channel activity (39).
Computational analysis has suggested that the D1790G mutation prolongs APD indirectly via calcium-sensitive pathways in a steeply inverse heart-rate dependent fashion. Taken together these results suggest that careful analysis of clinical data for carriers of these C-terminal mutations under a wide variety of conditions in which critical parameters such as heart rate and sympathetic tone can be controlled will be extremely useful in dissecting the crucial properties of these mutant channels that cause these inherited arrhythmias and the clinical conditions that are most likely to exacerbate fatal events in carriers of the specific gene defects. mutations. The time-dependence of the onset of Im inactivation was measured using a two pulses protocol (Test and inset). Peak P 2 current was normalized to peak P 1 current. The resulting P 2 /P 1 ratio was then further normalized to the maximal ratio and Arrows with tails indicate steady state currents for each pulse frequency.
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